No Data
No Data
Notable Analyst Calls This Week: Nike, Micron and FedEx Among Top Picks
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $8
Needham analyst Serge Belanger maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 39.8% an
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Joseph Pantginis maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate
Express News | HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Esperion Shares Rise on Monetization of European Royalties
By Don Nico Forbes Shares in Esperion Therapeutics rose 31% in premarket trading after the company signed a purchase agreement with Omers Life Sciences concerning its Daiichi Sankyo royalties in Euro
Esperion Therapeutics Shares Are Trading Higher After the Company Announced That It Entered Into a Royalty Purchase Agreement With OMERS Life Sciences.
Esperion Therapeutics Shares Are Trading Higher After the Company Announced That It Entered Into a Royalty Purchase Agreement With OMERS Life Sciences.
No Data